Cowen resumed coverage of Seer with a rating of Outperform
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/5/2023 | $10.00 | Neutral | JP Morgan |
| 1/4/2023 | $9.00 → $6.50 | Neutral → Underperform | BofA Securities |
| 8/11/2022 | $20.00 → $12.00 | Overweight → Neutral | JP Morgan |
| 3/1/2022 | $23.00 → $21.00 | Equal-Weight | Morgan Stanley |
| 2/15/2022 | $46.00 → $23.00 | Equal-Weight | Morgan Stanley |
| 10/15/2021 | Outperform | Cowen | |
| 8/13/2021 | $55.00 → $50.00 | Equal-Weight | Morgan Stanley |
10-Q - Seer, Inc. (0001726445) (Filer)
8-K - Seer, Inc. (0001726445) (Filer)
8-K - Seer, Inc. (0001726445) (Filer)
REDWOOD CITY, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today reported financial results for the third quarter ended September 30, 2024. Recent Highlights Achieved revenue of $4.0 million for the third quarter of 2024Entered into a co-marketing and sales agreement with Thermo Fisher Scientific to further enhance access and expand global reach to deep, unbiased proteomics at scalePresented multiple posters and featured in several presentations at the HUPO World Congress showcasing the use of the Proteograph Product Suite in Alzheimer's, population health, xenotransplantation
REDWOOD CITY, Calif., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that it will report financial results for the third quarter 2024 on Wednesday, November 6, 2024. Company management will be webcasting a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the Investor section of Seer's website at investor.seer.bio. An archived replay will be available on the company's website following the event. About SeerSeer is a life sciences company developing transformative products that open a new g
REDWOOD CITY, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today reported financial results for the second quarter ended June 30, 2024. Recent Highlights Achieved revenue of $3.1 million for the second quarter of 2024Launched the Seer Technology Access Center (STAC) in Europe, providing researchers with end-to-end services from sample to dataDemonstrated how the Proteograph Product Suite can uncover differentiated insights into plasma proteomic changes that occur during spaceflight through customer publications in Nature and Nature CommunicationsEnded the quarter with $344.6 m
REDWOOD CITY, Calif., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced it ranked No. 57 on the Deloitte Technology Fast 500™, a ranking of the 500 fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies in North America, now in its 30th year. Seer grew 2,440% during this period. Seer's President and CFO, David Horn, credits increased adoption of Seer's Proteograph Product Suite, as well as new discoveries made by its customers across neurodegenerative disease, cancer, and metabolic disease, with the company's 2,440% revenue
REDWOOD CITY, Calif., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced company management will be participating in the following investor conferences: Guggenheim Inaugural Healthcare Innovation Conference in Boston, MAFireside chat on Monday, November 11th at 11:30 a.m. Eastern TimeCanaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum in New York, NYFireside chat on Thursday, November 21st at 10:00 a.m. Eastern Time Live webcasts of the sessions will be available on the Investor section of Seer's website at investor.seer.bio. Archived replays will be available
REDWOOD CITY, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today reported financial results for the third quarter ended September 30, 2024. Recent Highlights Achieved revenue of $4.0 million for the third quarter of 2024Entered into a co-marketing and sales agreement with Thermo Fisher Scientific to further enhance access and expand global reach to deep, unbiased proteomics at scalePresented multiple posters and featured in several presentations at the HUPO World Congress showcasing the use of the Proteograph Product Suite in Alzheimer's, population health, xenotransplantation
Seer (NASDAQ:SEER) reported quarterly losses of $(0.32) per share which beat the analyst consensus estimate of $(0.34) by 5.88 percent. This is a 15.79 percent increase over losses of $(0.38) per share from the same period last year. The company reported quarterly sales of $3.066 million which missed the analyst consensus estimate of $3.800 million by 19.32 percent. This is a 24.35 percent decrease over sales of $4.053 million the same period last year.
JP Morgan resumed coverage of Seer with a rating of Neutral and set a new price target of $10.00
BofA Securities downgraded Seer from Neutral to Underperform and set a new price target of $6.50 from $9.00 previously
JP Morgan downgraded Seer from Overweight to Neutral and set a new price target of $12.00 from $20.00 previously
4 - Seer, Inc. (0001726445) (Issuer)
4 - Seer, Inc. (0001726445) (Issuer)
4 - Seer, Inc. (0001726445) (Issuer)
SC 13G/A - Seer, Inc. (0001726445) (Subject)
SC 13G/A - Seer, Inc. (0001726445) (Subject)
SC 13G/A - Seer, Inc. (0001726445) (Subject)
REDWOOD CITY, Calif., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced it has appointed Dr. Nicolas Roelofs to serve on its Board of Directors. "Nick is a fantastic addition to our board, bringing over 35 years of broad operational and advisory experience with leading healthcare, life science tools, and diagnostics companies," said Omid Farokhzad, Chair and CEO of Seer. "His extensive experience and insights will be valuable as we advance our mission of opening up a new gateway to the proteome." "I'm excited to work with the Seer team and leverage my experience in the life
REDWOOD CITY, Calif., March 16, 2022 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER), a life sciences company commercializing a disruptive new platform for proteomics, announced today the appointment of Scott D. Thomas as Chief Commercial Officer effective March 21, 2022. Mr. Thomas joins Seer from Singular Genomics, where he served as Senior Vice President, Sales and Marketing. Prior to Singular, he spent over two decades with increasing commercial responsibilities within the life sciences industry, including 11 years at Illumina. "I'm thrilled to welcome Scott, whose leadership and breadth of expertise in the commercialization of life sciences tools complements the balance of our talented
REDWOOD CITY, Calif., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Seer, Inc., (NASDAQ:SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced it has appointed Meeta Gulyani to serve on its Board of Directors. Ms. Gulyani is currently Executive Vice President, Head of Strategy, Business Development and Transformation for the Life Science business of Merck KGaA, Darmstadt, Germany, a global science and technology company, which operates as MilliporeSigma in the U.S. and Canada. "Meeta is a seasoned life sciences and pharma leader with global experience across markets, including Asia, an important market for Seer, and we are really pleased to welcome Me